FAculty directory

Back to alphabetical index

Martin W. Adler, PhD

Director Emeritus and Senior Advisor, Center for Substance Abuse Research

Laura H. Carnell Professor of Pharmacology
Executive Officer, College on Problems of Drug Dependence

Telephone:  215-707-3242

Fax:  215-707-1904

Email: baldeagl@temple.edu

Center for Substance Abuse Research

Department of Pharmacology

BA, New York University, New York

 

BS, Brooklyn College of Pharmacy, New York

 

MS, Columbia University, New York

 

PhD, Albert Einstein College of Medicine, New York

 

Return to top

Dr. Adler's laboratory has shown that the endogenous opioid system (receptors and ligands) is involved in a number of physiological and pathological processes including analgesia, thermoregulation, and brain excitability. These opioid systems produce their biological effects as part of a cascade of events that involve a number of neuropeptides and neurotransmitters. More recently, the interactions of opioids, cytokines and chemokines in the brain have been studied with regard to pain, thermoregulation and immunoregulation. The interactions of opioids with other abused drugs, especially cannabinoids, is a major focus of the laboratory.

Return to top

Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

19906780. Benamar K, Addou S, Yondorf M, Geller EB, Eisenstein TK, Adler MW, INTRAHYPOTHALAMIC INJECTION OF THE HIV-1 ENVELOPE GLYCOPROTEIN (GP120) INDUCES FEVER VIA INTERACTION WITH THE CHEMOKINE SYSTEM. J Pharmacol Exp Ther :()2009 Nov 11

19558543. Benamar K, Yondorf M, Geller EB, Eisenstein TK, Adler MW, Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. Br J Pharmacol 157:7(1225-31)2009 Aug

19332079. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF, CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res 78:1(86-94)2009 Jun

19255856. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF, Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 4:2(249-59)2009 Jun

18727928. Benamar K, Geller EB, Adler MW, A new brain area affected by 3,4-methylenedioxymethamphetamine: A microdialysis-biotelemetry study. Eur J Pharmacol 596:1-3(84-8)2008 Oct 31

18656466. Benamar K, Geller EB, Adler MW, Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats. Eur J Pharmacol 592:1-3(93-5)2008 Sep 11

18533278. Finley MJ, Chen X, Bardi G, Davey P, Geller EB, Zhang L, Adler MW, Rogers TJ, Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. J Neuroimmunol 197:2(114-23)2008 Jul 15

18304750. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF, Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152:3(753-60)2008 Mar 27

18281594. Benamar K, Geller EB, Adler MW, First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain. J Pharmacol Exp Ther 325:2(641-5)2008 May

19248685. Baty DE, Zhang M, Li H, Erb CJ, Adler MW, Ganea D, Loftus CM, Jallo JI, Tuma RF, Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury. Clin Neurosurg 55:(172-7)2008

17898318. Benamar K, Yondorf M, Barreto VT, Geller EB, Adler MW, Deletion of mu-opioid receptor in mice alters the development of acute neuroinflammation. J Pharmacol Exp Ther 323:3(990-4)2007 Dec

17640739. Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW, Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol 189:1-2(17-22)2007 Sep

17459345. Chen X, Geller EB, Rogers TJ, Adler MW, The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats. Brain Res 1153:(52-7)2007 Jun 11

17245417. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF, Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27:7(1387-96)2007 Jul

17194800. Benamar K, Yondorf M, Meissler JJ, Geller EB, Tallarida RJ, Eisenstein TK, Adler MW, A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. J Pharmacol Exp Ther 320:3(1127-33)2007 Mar

17173891. Chen X, Geller EB, Adler MW, Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test. Eur J Pharmacol 557:1(32-6)2007 Feb 14

17049756. Chen X, Geller EB, Rogers TJ, Adler MW, Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats. Drug Alcohol Depend 88:1(36-41)2007 Apr 17

16926415. Feng P, Truant AL, Meissler JJ Jr, Gaughan JP, Adler MW, Eisenstein TK, Morphine withdrawal lowers host defense to enteric bacteria: spontaneous sepsis and increased sensitivity to oral Salmonella enterica serovar Typhimurium infection. Infect Immun 74:9(5221-6)2006 Sep

16594639. Adler MW, Geller EB, Chen X, Rogers TJ, Viewing chemokines as a third major system of communication in the brain. AAPS J 7:4(E865-70)2006 Jan 6

16513108. Feng P, Rahim RT, Cowan A, Liu-Chen LY, Peng X, Gaughan J, Meissler JJ Jr, Adler MW, Eisenstein TK, Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit. Eur J Pharmacol 534:1-3(250-7)2006 Mar 18

Return to top